Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Check-Cap Ltd. reports developments as an Israel-incorporated clinical-stage medical diagnostics company with Nasdaq-listed ordinary shares. Recurring news for CHEK centers on shareholder voting matters, governance actions, material agreements, capital-structure proposals, clinical or regulatory disclosures, and operating and financial results.
Company updates also include annual meeting outcomes, board and proxy matters, transaction-related disclosures, and public-company status issues tied to its reporting obligations and exchange listing requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Check-Cap Ltd. (NASDAQ: CHEK, CHEKZ) announced financial results for Q4 and the full year ended December 31, 2022. The company reported a net loss of $3.7 million for Q4 2022, down from $5.5 million in Q4 2021. R&D expenses for the year rose to $14.3 million from $12.3 million, while general and administrative expenses increased to $5.8 million compared to $5.0 million in 2021. The company’s cash position at year-end was $42.1 million, which is projected to fund operations into Q4 2024. However, the initiation of the powered portion of its pivotal U.S. study is postponed as current efficacy results do not meet the required goals.